Company Overview

Phibro Animal Health Corporation (NASDAQ: PAHC) is a diversified global animal health and mineral nutrition company focused on products that support livestock, poultry, aquaculture, and companion animal health. The company operates primarily in the animal health industry, with activities spanning medicated feed additives, nutritional specialty products, vaccines, and mineral nutrition solutions. Its core revenue drivers include antimicrobial products, nutritional performance products, and vaccine solutions used by commercial animal producers and veterinarians. The company serves customers across the poultry, swine, beef, dairy, and aquaculture sectors, as well as industrial and specialty mineral markets through its mineral nutrition operations.

Phibro traces its origins to the former Philipp Brothers commodity business and evolved into a dedicated animal health enterprise through acquisitions, product development, and expansion into international markets. The company positions itself as a specialized provider with long-standing expertise in food animal production efficiency and disease prevention. Its competitive positioning is supported by established regulatory approvals, global distribution capabilities, manufacturing infrastructure, and long-term relationships with large-scale agricultural producers and distributors.

Business Operations

Phibro operates through three principal business segments: Animal Health, Mineral Nutrition, and Performance Products. The Animal Health segment is the company’s primary business and includes antimicrobial feed additives, anticoccidials, vaccines, nutritional specialty products, and related animal health solutions. Revenue is generated through product sales to integrated livestock producers, feed manufacturers, distributors, and veterinarians. The Mineral Nutrition segment supplies trace minerals and nutrient ingredients used in animal nutrition and industrial applications, while the Performance Products segment includes specialty chemicals and ingredients.

The company maintains manufacturing, research, and distribution operations across multiple countries, including facilities in the United States, Brazil, and other international markets. Phibro controls proprietary product formulations, vaccine technologies, and manufacturing assets that support its vertically integrated operations. Key subsidiaries include Prince Agri Products, Inc. and other operating entities supporting regional distribution and production activities. The company also collaborates with distributors, commercial producers, and research organizations to support product commercialization and regulatory compliance in global markets.

Strategic Position & Investments

Phibro’s strategic direction has centered on expanding its portfolio of nutritional specialty products, vaccines, and differentiated animal health technologies while maintaining its core medicated feed additive business. Growth initiatives have included investment in biologics, poultry vaccines, and environmentally focused nutritional products designed to improve animal productivity and feed efficiency. The company has also emphasized international market expansion, particularly in emerging livestock production regions where protein demand continues to increase.

The company has completed targeted acquisitions and investments intended to broaden product capabilities and geographic reach. Notable transactions in recent years have included the acquisition of Zoetis Inc.’s medicated feed additive portfolio and investments related to vaccine and nutrition technologies. Phibro has also increased investment in research and development supporting alternatives to traditional antibiotic usage, immune support technologies, and precision nutrition applications. Public filings and investor materials indicate continued emphasis on operational efficiency, product diversification, and growth in higher-margin specialty products.

Geographic Footprint

Phibro Animal Health Corporation is headquartered in Teaneck, New Jersey, and operates across North America, Latin America, Europe, Asia-Pacific, and the Middle East/Africa regions. The company markets products in more than 80 countries through direct sales operations, distributors, and regional partnerships. The United States remains a major market, though international operations contribute a substantial portion of overall revenue.

The company maintains manufacturing and commercial operations in countries including Brazil, Israel, China, and several European markets, supporting both local production and export activity. Its international footprint is closely tied to global protein production trends, particularly in poultry and swine markets. Phibro’s presence in both developed and emerging agricultural economies provides exposure to diverse customer bases and varying livestock production systems.

Leadership & Governance

Phibro Animal Health Corporation operates under a leadership structure combining industry, operational, scientific, and financial expertise. The company’s governance framework is overseen by its board of directors and executive leadership team, with strategic priorities focused on sustainable growth, operational discipline, and innovation in animal health and nutrition. Public disclosures and executive communications emphasize long-term customer relationships, regulatory compliance, and scientific product development as central components of corporate strategy.

Key executives include:

• Jack C. Bendheim – Chairman of the Board, President and Chief Executive Officer
• Glenn David – Chief Financial Officer
• Larry L. Miller – Chief Operating Officer
• Richard Johnson – Senior Vice President, General Counsel and Corporate Secretary
• Allan Goldberg – Senior Vice President, Global Strategic Marketing

Information in this overview has been verified against publicly available company disclosures including SEC filings, annual reports, investor presentations, and reporting from established financial and market information providers. Where details varied between disclosures and third-party summaries, preference was given to the most recent company-filed documents.